AMGN terminates phase-3 trials of rilotumumab* due to safety problem: http://finance.yahoo.com/news/amgen-announces-termination-amgen-sponsored-141500865.html Amgen today announced the termination of all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer, including the Phase 3 RILOMET-1 and RILOMET-2 studies. Amgen's decision is based on a planned safety review by the RILOMET-1 independent data monitoring committee that found an increase in the number of deaths in the rilotumumab and chemotherapy treatment arm when compared to the chemotherapy treatment only arm. *F/k/a/ AMG 102.